NOVT
Novanta
Summary
What they do:
Design and manufacture precision motion systems, photonics components, and robotic automation subsystems — including the sole-source air bearing spindles used to drill the high-density PCBs that carry NVIDIA GPUs, plus laser scanning and robotic end-of-arm tooling for semiconductor and medical applications.
Why they matter:
Novanta's air bearing spindles are the only qualified supplier for drilling AI GPU boards. Without these spindles, NVIDIA's GPU boards cannot be manufactured. This sole-source position makes Novanta a hidden bottleneck in the AI infrastructure chain — one that almost nobody is watching because the company is better known for medical robotics.
Recent performance:
Record FY2025 revenue of $981M, biggest year ever. Q4 2025 revenue up 9% reported with bookings surging 25% YoY (1.11 book-to-bill). Every single business unit delivered double-digit bookings growth and positive book-to-bill in the same quarter — first time since 2022. New product sales grew 80%+ YoY in Q4 (vitality index 24%). Guided 2026 revenue $1.03–1.05B (4–6% organic growth). Stock ~$126, market cap ~$4.5B. Reports Q1 2026 on May 12.
Our Verdict
A quality compounder with a hidden AI chokepoint — sole-source GPU board drilling spindles create a direct dependency to NVIDIA production the market has not fully priced, while physical AI robotics provides a second secular tailwind beyond the semiconductor cycle.
Structural trends
Structural
81
/ 100
Moat
7/10
Sole-source GPU board drilling, 25+ years air bearing engineering, diversified cash flow
AI Exp.AI Exposure
Embedded~15% AI
Play Type
EmergingAI Growth
~30%
Rel. Value
45
FAIRNovanta is a $4.5B precision technology company that most investors associate with medical robotics and laser surgery systems. But buried inside its Automation Enabling Technologies segment is a critical piece of AI infrastructure: the air bearing spindles that drill the high-density printed circuit boards carrying NVIDIA GPUs and other AI accelerators.
These aren't ordinary drill spindles. AI GPU boards require extremely tight tolerances — thousands of vias drilled through multi-layer PCBs at positions accurate to within microns. Air bearing spindles rotate at 150,000–350,000 RPM with virtually zero vibration, enabling the drilling precision that these complex boards demand. Novanta's spindles are currently the only qualified supplier for this application. As demand for AI compute infrastructure scales, every additional GPU board requires drilling on Novanta's spindles.
The company operates in two segments. Automation Enabling Technologies (47% of FY2025 revenue) includes precision motion, laser beam delivery, robotic end-of-arm tooling, and the air bearing spindle business — subdivided into a robotics & automation business (6% Q4 YoY growth, 1.13 book-to-bill, ~25% bookings growth) and a precision manufacturing business (Q4 revenue still -3% YoY but inflecting — 8% sequential growth, 1.2 book-to-bill, ~50% bookings growth, $100M+ backlog). Medical Solutions (53% of revenue) provides advanced surgery systems (insufflators, robotic surgery components, arthroscopy), precision medicine (life sciences, multiomics, RFID), and medical consumables (15% of total company revenue, growing double digits). The medical business is a steady cash flow generator and increasingly a growth engine; the automation business is where the AI growth lives.
Novanta has compounded revenue at a high single-digit CAGR over the past decade, supplemented by disciplined acquisitions. FY2025 revenue hit a record $981M. FY2025 adjusted gross margin was 46%, adjusted EBITDA $221M (implied). The company guided FY2026 revenue of $1.03–1.05B with adjusted EBITDA of $245–250M (~24% margin, low double-digit YoY growth), adjusted EPS of $3.50–3.65 (+11% YoY), and operating cash flow of $145–185M (more than double FY2025's $64M). The organic growth cadence accelerates through the year: Q1 +1–3%, Q2 +5–7%, with similar levels in H2. Bookings are running at 1.11x revenue, and management has flagged $1.5B in acquisition capacity available for deployment in 2026. The M&A pipeline is described as the largest in CEO Glastra's tenure, focused on mid-to-larger opportunities in medical technologies, medical consumables, bioprocessing, and embedded software.
Supply Chain Dependencies
The Catch
Novanta trades at ~38x trailing adjusted EPS ($3.29 FY2025) and ~35x forward adjusted EPS ($3.50–3.65 guided), where the AI narrative rests on a business (GPU board drilling spindles) that represents only 5–8% of revenue today, supplemented by early-stage WFE and physical AI vectors. The sole-source position is real and was explicitly confirmed by the CEO on the Q4 call, but the financial materiality is not yet proven at the consolidated level. If the market decides Novanta is a quality medical/industrial compounder rather than an AI infrastructure play, the multiple compresses to 25–30x forward, implying $90–110. The physical AI robotics thesis has advanced (warehouse robotics content win ramping, humanoid partnerships, ISO standards work) but may take 2–3 years to contribute meaningfully to revenue. Near-term execution risk lies in completing regional manufacturing transfers by Q2 2026 and recovering from the Q4 gross margin and cash flow miss.
If They Win
If the AI compute buildout sustains through 2028 and GPU board complexity keeps increasing, Novanta's sole-source spindle position compounds quietly from 5% to 15% of revenue — a $150M+ annual business with monopoly pricing power and zero competitors. Simultaneously, physical AI explodes (warehouse automation, surgical robots, industrial cobots), and Novanta's precision motion, vision, and end-of-arm tooling portfolio rides the wave. Revenue reaches $1.5B by 2029 with 26% EBITDA margins. The company is re-rated from medical/industrial to "the precision infrastructure layer of physical AI" — a classification that commands 35x+ forward earnings.
Others in Build the Machines That Make the Chip
Not financial advice. All scores generated via AI algorithms using public data.